"These results represent an unprecedented advance for patients with extensive-stage small cell lung cancer, demonstrating a magnitude of survival benefit rarely seen in this aggressive disease," said ...
Amgen established its presence in Kendall Square in 2001, before the area became a global life sciences hub. When Amgen established a presence in the Kendall Square area of Cambridge in 2001, the ...
THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE ® (tezepelumab-ekko) ...
THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress ...
After a missed spinal fracture left her feeling fragile and isolated, Dona became an advocate for women living with postmenopausal osteoporosis. This World Osteoporosis Day, Dona is sharing her story ...
See how teams are reducing environmental impact across Amgen.
Collaborations With Guardant Health and QIAGEN Will Develop Blood- and Tissue-Based Companion Diagnostics For Investigational KRAS(G12C) Inhibitor AMG 510 Amgen Oncology is searching for and finding ...
THOUSAND OAKS, Calif., Feb. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023. "Robust growth ...
THOUSAND OAKS, Calif., Aug. 27, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 CROSSING trial of TEZSPIRE ® (tezepelumab-ekko) in ...
* The known adjustments are presented net of their related tax impact, which amount to approximately $2.39 per share. (a) The adjustments primarily include noncash amortization of intangible assets ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to ...
* The known adjustments are presented net of their related tax impact, which amount to approximately $1.01 per share. (a) The adjustments include noncash amortization of intangible assets and fair ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results